MA49560A - Composés cétoniques bicycliques et leurs procédés d'utilisation - Google Patents
Composés cétoniques bicycliques et leurs procédés d'utilisationInfo
- Publication number
- MA49560A MA49560A MA049560A MA49560A MA49560A MA 49560 A MA49560 A MA 49560A MA 049560 A MA049560 A MA 049560A MA 49560 A MA49560 A MA 49560A MA 49560 A MA49560 A MA 49560A
- Authority
- MA
- Morocco
- Prior art keywords
- bicyclic
- processes
- ketonic compounds
- ketonic
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762532767P | 2017-07-14 | 2017-07-14 | |
| PCT/EP2018/068998 WO2019012063A1 (fr) | 2017-07-14 | 2018-07-12 | Composés cétoniques bicycliques et leurs procédés d'utilisation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA49560A true MA49560A (fr) | 2020-05-20 |
| MA49560B1 MA49560B1 (fr) | 2024-05-31 |
Family
ID=62916677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA49560A MA49560B1 (fr) | 2017-07-14 | 2018-07-12 | Composés cétoniques bicycliques et leurs procédés d'utilisation |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US11098058B2 (fr) |
| EP (2) | EP4397309A3 (fr) |
| JP (2) | JP7258843B2 (fr) |
| KR (2) | KR20240065201A (fr) |
| CN (1) | CN110914271A (fr) |
| AR (1) | AR112274A1 (fr) |
| AU (3) | AU2018300043B2 (fr) |
| BR (1) | BR112020000771A2 (fr) |
| CA (2) | CA3067944C (fr) |
| CL (1) | CL2020000101A1 (fr) |
| CO (1) | CO2020000134A2 (fr) |
| CR (1) | CR20200002A (fr) |
| DK (1) | DK3652178T3 (fr) |
| ES (1) | ES2973661T3 (fr) |
| FI (1) | FI3652178T3 (fr) |
| HR (1) | HRP20240354T1 (fr) |
| HU (1) | HUE065793T2 (fr) |
| IL (2) | IL294961A (fr) |
| LT (1) | LT3652178T (fr) |
| MA (1) | MA49560B1 (fr) |
| NZ (1) | NZ760749A (fr) |
| PH (1) | PH12020500105A1 (fr) |
| PL (1) | PL3652178T3 (fr) |
| PT (1) | PT3652178T (fr) |
| RS (1) | RS65308B1 (fr) |
| SG (1) | SG11202000333UA (fr) |
| SI (1) | SI3652178T1 (fr) |
| TW (1) | TWI805595B (fr) |
| UA (1) | UA125448C2 (fr) |
| WO (1) | WO2019012063A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201831478A (zh) | 2016-12-02 | 2018-09-01 | 瑞士商赫孚孟拉羅股份公司 | 雙環醯胺化合物及其使用方法 |
| FI3652178T3 (fi) | 2017-07-14 | 2024-03-19 | Hoffmann La Roche | Bisyklisiä ketoniyhdisteitä ja niiden käyttömenetelmiä |
| MA50503A (fr) | 2017-10-31 | 2020-09-09 | Hoffmann La Roche | Sulfones et sulfoxydes bicycliques et procédés d'utilisation associés |
| AR119673A1 (es) * | 2019-01-11 | 2022-01-05 | Hoffmann La Roche | Compuestos bicíclicos de cetona y métodos para utilizarlos |
| WO2021198981A1 (fr) | 2020-04-01 | 2021-10-07 | Janssen Biopharma, Inc. | Composés antiviraux et leurs utilisations |
| EP4144720A4 (fr) * | 2020-04-27 | 2024-06-19 | Autotac Inc. | Composé en tant que ligand du domaine ubr-box |
| CA3214802A1 (fr) | 2021-04-02 | 2022-10-06 | Genentech, Inc. | Procedes de fabrication de composes cetoniques bicycliques |
| WO2023039795A1 (fr) * | 2021-09-16 | 2023-03-23 | 维泰瑞隆（北京）生物科技有限公司 | Inhibiteur de la kinase rip1 et son utilisation |
| TW202406906A (zh) * | 2022-05-19 | 2024-02-16 | 美商默沙東有限責任公司 | Ripk1抑制劑及使用方法 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1620508A1 (de) | 1965-07-23 | 1969-09-18 | Thomae Gmbh Dr K | Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3948903A (en) | 1972-12-15 | 1976-04-06 | Parke, Davis & Company | Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| EP0102324A3 (fr) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipides et composés tensio-actifs en phase aqueuse |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| GB8610530D0 (en) | 1986-04-30 | 1986-06-04 | Fbc Ltd | Herbicides |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| CA2141216A1 (fr) | 1992-07-27 | 1994-02-03 | Michael J. Micklus | Ciblage de liposomes vers la barriere hemato-encephalique |
| US6080772A (en) | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
| WO1998056376A1 (fr) | 1997-06-13 | 1998-12-17 | Sugen, Inc. | Nouveaux composes heteroaryle pour la modulation de la transduction de signaux cellulaires associee aux enzymes proteine tyrosine |
| CA2399791A1 (fr) * | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Modulateurs de recepteurs aux cannabinoides, leurs procedes de preparation et utilisations de modulateurs de recepteurs aux cannabinoides pour le traitement de maladies respiratoires et non respiratoires |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| US20020065259A1 (en) | 2000-08-30 | 2002-05-30 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| DE60234057D1 (de) | 2001-07-25 | 2009-11-26 | Raptor Pharmaceutical Inc | Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| EP1572113B1 (fr) | 2002-08-26 | 2017-05-17 | Takeda Pharmaceutical Company Limited | Compose modulateur de recepteur de calcium et utilisation associee |
| KR101186210B1 (ko) | 2002-12-03 | 2012-10-08 | 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 | 혈뇌장벽을 통과하는 물질 수송용 인공 저밀도 지단백질 운반체 |
| ES2314418T3 (es) | 2003-05-02 | 2009-03-16 | Elan Pharmaceuticals, Inc. | Derivados de amidas del acido 4-bromo-5-(2-clorobenzoilamino)-1h-pirazol-3-carboxicilico y compuestos relacionados como antagonistas del receptor b1 de bradiquinina para el tratamiento de enfermedades inflamatorias. |
| EP1663239A4 (fr) | 2003-09-10 | 2008-07-23 | Cedars Sinai Medical Center | Administration assistee par les canaux potassiques d'agents a travers la barriere hemato-encephalique |
| US20080188478A1 (en) | 2005-04-26 | 2008-08-07 | Pfizer Inc. | Compounds Useful In Therapy |
| EP2083009A1 (fr) | 2008-01-22 | 2009-07-29 | Grünenthal GmbH | Composés tétrahydroimidazopyridine substitués et leur utilisation en tant que médicament |
| US8299077B2 (en) | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| CN101824036A (zh) | 2009-03-05 | 2010-09-08 | 上海恒瑞医药有限公司 | 四氢咪唑并[1，5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用 |
| TWI421252B (zh) | 2009-07-09 | 2014-01-01 | Irm Llc | 用於治療寄生蟲疾病之化合物及組合物 |
| KR20140096100A (ko) | 2011-11-03 | 2014-08-04 | 에프. 호프만-라 로슈 아게 | 이환 피페라진 화합물 |
| BR112014026176A2 (pt) | 2012-05-22 | 2017-06-27 | Hoffmann La Roche | dipiridilaminas substituídas e usos das mesmas |
| TWI498325B (zh) | 2013-01-18 | 2015-09-01 | Hoffmann La Roche | ３－取代吡唑及其用途 |
| TWI648274B (zh) * | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| RU2015147601A (ru) | 2013-05-01 | 2017-06-05 | Ф. Хоффманн-Ля Рош Аг | С-связанные гетероциклоалкилзамещенные пиримидины и их применения |
| UA121016C2 (uk) | 2013-05-01 | 2020-03-25 | Ф. Хоффманн-Ля Рош Аг | Бігетероарильні сполуки та їх застосування |
| CN105473554B (zh) | 2013-07-10 | 2019-08-13 | 沃泰克斯药物股份有限公司 | 作为离子通道调节剂的稠合的哌啶酰胺类 |
| MX2016008110A (es) | 2013-12-20 | 2016-08-19 | Hoffmann La Roche | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. |
| AU2015238541B2 (en) | 2014-03-26 | 2019-09-19 | F. Hoffmann-La Roche Ag | Condensed [1,4]diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors |
| AU2015304851A1 (en) | 2014-08-21 | 2017-02-23 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as RIP1 kinase inhibitors as medicaments |
| WO2016128908A1 (fr) * | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Composés bicycliques, compositions et applications médicinales correspondantes |
| WO2016142310A1 (fr) | 2015-03-09 | 2016-09-15 | F. Hoffmann-La Roche Ag | Inhibiteurs de dlk tricycliques et utilisations associées |
| MX2017016482A (es) * | 2015-07-02 | 2018-03-08 | Hoffmann La Roche | Lactamas biciclicas y metodos de uso de las mismas. |
| WO2017096301A1 (fr) | 2015-12-04 | 2017-06-08 | Denali Therapeutics Inc. | Inhibiteurs dérivés d'isoxazolidine de protéine kinase 1 interagissant avec un récepteur (ripk 1) |
| US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| JP6974331B2 (ja) | 2016-02-05 | 2021-12-01 | デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. | 化合物、組成物及び方法 |
| TW201831478A (zh) | 2016-12-02 | 2018-09-01 | 瑞士商赫孚孟拉羅股份公司 | 雙環醯胺化合物及其使用方法 |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| CN110169087B (zh) | 2017-01-05 | 2021-04-20 | 微软技术许可有限责任公司 | 重定向音频输出 |
| FI3652178T3 (fi) | 2017-07-14 | 2024-03-19 | Hoffmann La Roche | Bisyklisiä ketoniyhdisteitä ja niiden käyttömenetelmiä |
| CN111201229B (zh) * | 2017-10-11 | 2024-08-23 | 豪夫迈·罗氏有限公司 | 用作rip1激酶抑制剂的二环化合物 |
| MA50503A (fr) | 2017-10-31 | 2020-09-09 | Hoffmann La Roche | Sulfones et sulfoxydes bicycliques et procédés d'utilisation associés |
-
2018
- 2018-07-12 FI FIEP18740815.8T patent/FI3652178T3/fi active
- 2018-07-12 AU AU2018300043A patent/AU2018300043B2/en active Active
- 2018-07-12 EP EP24152498.2A patent/EP4397309A3/fr active Pending
- 2018-07-12 LT LTEPPCT/EP2018/068998T patent/LT3652178T/lt unknown
- 2018-07-12 CA CA3067944A patent/CA3067944C/fr active Active
- 2018-07-12 MA MA49560A patent/MA49560B1/fr unknown
- 2018-07-12 IL IL294961A patent/IL294961A/en unknown
- 2018-07-12 SG SG11202000333UA patent/SG11202000333UA/en unknown
- 2018-07-12 SI SI201831080T patent/SI3652178T1/sl unknown
- 2018-07-12 HU HUE18740815A patent/HUE065793T2/hu unknown
- 2018-07-12 US US16/034,207 patent/US11098058B2/en active Active
- 2018-07-12 CA CA3185865A patent/CA3185865A1/fr active Pending
- 2018-07-12 PL PL18740815.8T patent/PL3652178T3/pl unknown
- 2018-07-12 ES ES18740815T patent/ES2973661T3/es active Active
- 2018-07-12 UA UAA202000831A patent/UA125448C2/uk unknown
- 2018-07-12 CN CN201880046714.2A patent/CN110914271A/zh active Pending
- 2018-07-12 DK DK18740815.8T patent/DK3652178T3/da active
- 2018-07-12 EP EP18740815.8A patent/EP3652178B1/fr active Active
- 2018-07-12 RS RS20240314A patent/RS65308B1/sr unknown
- 2018-07-12 BR BR112020000771-4A patent/BR112020000771A2/pt unknown
- 2018-07-12 TW TW107124048A patent/TWI805595B/zh active
- 2018-07-12 CR CR20200002A patent/CR20200002A/es unknown
- 2018-07-12 HR HRP20240354TT patent/HRP20240354T1/hr unknown
- 2018-07-12 KR KR1020247014915A patent/KR20240065201A/ko active Search and Examination
- 2018-07-12 AR ARP180101941 patent/AR112274A1/es unknown
- 2018-07-12 KR KR1020207004030A patent/KR102664604B1/ko active IP Right Grant
- 2018-07-12 PT PT187408158T patent/PT3652178T/pt unknown
- 2018-07-12 IL IL271981A patent/IL271981B/en unknown
- 2018-07-12 NZ NZ760749A patent/NZ760749A/en unknown
- 2018-07-12 WO PCT/EP2018/068998 patent/WO2019012063A1/fr active Application Filing
- 2018-07-12 JP JP2020501256A patent/JP7258843B2/ja active Active
-
2020
- 2020-01-08 CO CONC2020/0000134A patent/CO2020000134A2/es unknown
- 2020-01-13 CL CL2020000101A patent/CL2020000101A1/es unknown
- 2020-01-14 PH PH12020500105A patent/PH12020500105A1/en unknown
-
2021
- 2021-01-12 US US17/147,449 patent/US11834461B2/en active Active
- 2021-06-26 AU AU2021204369A patent/AU2021204369A1/en not_active Abandoned
-
2023
- 2023-04-05 JP JP2023061174A patent/JP2023085449A/ja active Pending
- 2023-05-25 AU AU2023203292A patent/AU2023203292A1/en active Pending
- 2023-11-21 US US18/516,014 patent/US20240300974A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43827A (fr) | Composés di-nucléotides cycliques et leurs procédés d'utilisation | |
| MA49560A (fr) | Composés cétoniques bicycliques et leurs procédés d'utilisation | |
| MA49858A (fr) | Composés, compositions et procédés | |
| MA49861A (fr) | Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation | |
| MA50063A (fr) | Composés, compositions et procédés | |
| MA46529A (fr) | Anticorps anti-lag-3 et leurs procédés d'utilisation | |
| MA42055A (fr) | Composés antimicrobiens et procédés de fabrication et d'utilisation de ceux-ci | |
| MA43389A (fr) | Anticorps anti-ox40 et leurs procédés d'utilisation | |
| MA44524A (fr) | Néoantigènes et leurs procédés d'utilisation | |
| MA44225A (fr) | Sulfonylurées et composés apparentés et leur utilisation | |
| MA50949A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
| MA52488A (fr) | Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation | |
| MA46770A (fr) | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation | |
| MA44507A (fr) | Récepteurs chimères de flt3 et leurs procédés d'utilisation | |
| MA43802A (fr) | Matières cellulosiques et procédés de fabrication et d'utilisation de celles-ci | |
| MA47576A (fr) | Composés inhibiteurs d'oga bicyclique | |
| MA43284A (fr) | Composés et leurs méthodes d'utilisation | |
| MA49014A (fr) | Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant | |
| MA39915A (fr) | Composés de pladiénolide pyridine et leurs procédés d'utilisation | |
| MA41558A (fr) | Compositions d'allergènes mélangés et leurs procédés d'utilisation | |
| MA55097A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA47691A (fr) | Anticorps anti-cd33 et leurs procédés d'utilisation | |
| MA47167A (fr) | Composés pyrazolopyrimidine et leurs procédés d'utilisation | |
| MA50045A (fr) | Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci | |
| MA54851A (fr) | Oxystérols et leurs procédés d'utilisation |